NRAS and acute myeloid leukemia: Table 4 shows the clinical outcome in pediatric AML patients. In the total group, there was no difference with regard to CR rate (NRASmutant, 66.7%; NRASwild, 69.5%; P = 0.43). Relapse was significantly more frequent in the AML patients with NRAS gene mutations (NRASmuant, 33.4 %; NRASwild, 30.2 %; P= 0.26).